GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.
Zacks.com on MSN1d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
GlobalData on MSN16d
EC approves GSK’s Jemperli-chemo combo for endometrial cancerThe European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent ...
GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...
GlobalData on MSN9d
GSK and University of Oxford partner for cancer vaccine researchGSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.
(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback